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Introduction: CYP2D6 protein activity can be inferred from the ratio of N-desmethyl-tamoxifen (NDMT)
to endoxifen (E). CYP2D6 polymorphisms are common and can affect CYP2D6 protein activity and E level.
Some retrospective studies indicate that E < 16 nM may relate to worse outcome.
Materials and methods: A target NDMT/E ratio was defined as associated with an E level of 15 nM in the
161 patient Test cohort of tamoxifen-treated patients, dichotomizing them into ‘Normal’ (NM) and ‘Slow’
(SM) CYP2D6 metabolizer groups. This ratio was then tested on a validation cohort of 52 patients. Pa-
tients were phenotyped based on the standard method (ultrarapid/extensive, intermediate or poor
metabolizers; UM/EM, IM, PM) or a simplified system based onwhether any variant allele (V) vs wildtype
(wt) was present (wt/wt, wt/V, V/V). Comprehensive CYP2D6 genotyping was undertaken on germline
DNA.
Results: A target NDMT/E ratio of 35 correlated with the 15 nM E level, dichotomizing patients into NM
(<35; N ¼ 117) and SM (>35; N ¼ 44) groups. The ratio was independently validated by a validation
cohort. The simplified systemwas better in predicting patients without slow metabolism, with specificity
and sensitivity of 96% and 44% respectively, compared with the standard method - sensitivity 81% and
specificity 83%.
Conclusions: The simplified classification system based on whether any variant was present better
identified patients who were truly not CYP2D6 slow metabolizers more accurately than the current
system. However, as CYP2D6 genotype is not the only determinant of endoxifen level, we recommend
that direct measurement of endoxifen should also be considered.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).and the University of New
wn, NSW, 2200, Australia.
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1. Introduction
Tamoxifen is an important endocrine therapy for hormone
sensitive breast cancer [1]. It is a selective estrogen receptor
modulator and a pro-drug that is metabolised extensively by cy-
tochrome P450 enzymes to produce active metabolites. Pharma-
cogenetic variability of Cytochrome P450 2D6 (CYP2D6)2 is one of
the key factors in the metabolism of tamoxifen, resulting in vari-
ability of active metabolite levels [3]. Of these, 4-OH-N-desme-
thyltamoxifen (endoxifen) and 4OH-tamoxifen are the most
antioestrogenic. Endoxifen is the most abundant [2] and is largely
responsible for tamoxifen’s effect on outcome [4,5]. Two retro-
spective datasets have shown that patients whose endoxifen levels
were <15 nM or <16 nM respectively, were associated with worse
cancer-related outcomes [6,7], suggesting a critical threshold for
tamoxifen effect. In addition to CYP2D6 activity, a number of other
factors are involved in determining endoxifen level, such as
CYP3A4, CYP2C9/19, UDP-glucuronosyltransferases and sulfo-
transferase activity, as well as compliance, use of food supplements
[8], BMI [9,10], menopausal status [11] and concomitant medica-
tions that inhibit CYP2D6 enzyme activity [4].
Single nucleotide polymorphisms of germline [12] CYP2D6 are
an important determinant of CYP2D6 activity and influence the
variability of many drugs including tamoxifen [13]. CYP2D6 is
highly polymorphic with over 100 known allelic variants [13] and
significant interethnic differences exist [14,15]. Guidelines have
been made which provide recommendations on tamoxifen dose
based on CYP2D6 genotype [16]. Alleles that are routinely examined
include *1, *2, *1 x N or *2 xN, *3, *4, *5, *6, *10, *17, *41, with *1
and *2 representing wild type normal function and with the others
associated with varying degrees of impaired function. The dip-
lotype of these is used to categorize a phenotype of CYP2D6 activity
[17] which was originally based on codeine metabolism and
extrapolated to tamoxifen [16]. This system defines four metabolic
activity categories, ranging from poor to ultrarapid. However, with
regards to tamoxifen, clinicians are ultimately concerned about
only identifying slow metabolizers (which imply low endoxifen
level) and it can be argued that such a complex, granular system is
unnecessary.
In this study, we assessed a simplified CYP2D6 phenotype sys-
tem in tamoxifen-treated patients to determine whether a dip-
lotype comprising any genetic variant could predict slow
metabolizer status and compared this with the standard, complex
classification. We directly assessed CYP2D6 activity by using the
ratio of tamoxifen metabolites to define patients with slow
metabolism.
2. Material and methods
Informed consent was obtained from all participants and the
study was conductedwith approval from the local Human Research
Ethics Committee, Westmead Hospital, Sydney, Australia.
A total of 159 patients were studied from Australia and 54 from
the Netherlands and were divided into test and validation cohorts,
with ultimately 161 patients in the test cohort and 52 patients in
the validation cohort. Germline CYP2D6 SNPs were measured in
each patient. All patients were women who were treated with
tamoxifen endocrine therapy for treatment of invasive hormone
sensitive breast cancer. Patients who were treated with concomi-
tant CYP2D6 inhibitors were excluded from this study.
In each cohort, patients were CYP2D6 genotyped from genomic
DNA isolated from blood using a high-salt method [18]. Briefly, all
DNA samples (5 ng/ml) were transferred into 384 well PCR plates for230genotyping. The genotyping analysis was performed as recom-
mended by the manufacturer with reagents included in the iPLEX
ADME PGx Pro genotyping kit (Agena) and the software and
equipment provided with the MassARRAY platform (Agena). In
brief, DNA samples were PCR amplified according manufacture
protocol. Subsequently, PCR products were treated with 0.5 U
shrimp alkaline phosphatase to neutralize unincorporated dNTPs.
Extension reactionwas carried out with iPLEX Pro extension before
purification using SpectroCLEAN resins. The cleaned extension
products were dispensed onto a 384 SpectroCHIP array using an
RS1000 Nanodispenser. Finally, the array was introduced into a
MassARRAY Compact mass spectrometer. Spectra were acquired
using SpectroAcquire software, and data analysis, including auto-
mated allele calling, was done using MassARRAY Typer software,
version 4.0.5.
The following CYP2D6 SNPs were measured: *1, *2 A; *31;
*51,*2 L; *35; *71, *3, *4, *4M, *6, *7, *8, *9, *10; *36; *37; *47; *49;
*52; *54; *57; *65; *72, *11, *12, *14 A, *14 B, *15, *17, *18, *19, *20,
*21 A, *21 B, *30, *40, *41, *42, *44, *56 A, *56 B, *58, *64, *69.
CYP2D6 phenotype was described using the clinical pharmacoge-
netics classification system based on codeine metabolism [17].
These are in order of highest function to lowest: ultrarapid
metabolizers (UM) and extensive metabolizers (EM), which we
classified together as EM, intermediate metabolizers (IM) and poor
metabolizers (PM). We also categorized each patient’s haplotype
using a simplified system defined by whether they were wild type
(wt; defined as *1, *2 or duplication) or had any variant (V) present.
Alleles other than *1 or *2 were classified as “Variant” alleles.
Diplotypes were then categorized as homozygous wt/wt, homo-
zygous V/V or heterozygous wt/V. Additionally, *9 and *15 which
are not classified by the current codeine based system were
considered to be partially functioning and non-functioning vari-
ants, respectively [19]. Hence *9/*9 and *15/*15 diplotypes were
considered IM and PM respectively, using the Crews categorization
[17], and V/V using our simplified system.
Each patient had tamoxifen and metabolites assessed on
plasma, after a minimum of eight weeks of daily dosing of
tamoxifen to ensure endoxifen steady state [20] had been reached.
Endoxifen and n-desmethyl hydroxy tamoxifen (NDMT) and other
tamoxifen metabolite levels were measured according to methods
as previously described in the Australian cohort [21] and in the
Dutch [22]. The tamoxifen metabolite results for the Australian and
Dutch patients were cross-validated. Endoxifen is produced by
CYP2D6 metabolism of NDMT and so CYP2D6 activity can be
described using the ratio of NDMT to endoxifen (NDMT/E). So we
could define the ratio associated with slow metabolism, we first
determined a NDMT/E associated with a low endoxifen level then
classified patients as normal metabolizers (NM) if below the cutoff
NDMT/E ratio and slow metabolizers (SM) if above the cutoff
NDMT/E ratio.
An E level of 15 nM6,7 was used to calculate the cut-off NDMT/E
ratio. The NDMT/E ratio vs E curve was best fitted with the expo-
nential equation:
NDMT/E ratio ¼ Ae-k*EDF where A & k were constants deter-
mined by obtaining the least sum of the differences between the
measured data and the fitted curve with the above described
equation using the solver function of Microsoft Excel spreadsheet
(Excel 2013, Microsoft, USA).
We compared this ratio to individual CYP2D6 genotypes to
define phenotypes associated with slow CYP2D6 activity using the
standard categorization method as well as a simplified system
based on the presence of absence of any CYP2D6 variant. We hy-
pothesized that the simplified system may more accurately cate-
gorize slow CYP2D6 metabolizer phenotype compared to the
standard method in tamoxifen-treated patients. We acknowledge
C.I. Lee, S.K. Low, R. Maldonado et al. The Breast 54 (2020) 229e234that genotyping analysis of CYP2D6 is complicated and that there
are many potential ways of defining phenotypes. We felt that our
method of distinguishing between variant and wildtype alleles
simplified the analysis and performed at least as well as the other
phenotyping methods based on genotype.Fig. 1. Test cohort: Mean NDMT/E per diplotype.3. Results
One hundred and sixty-one patients were prospectively
enrolled in the test cohort, comprising three quarters Australian
and one quarter Dutch patients. The validation cohort comprised
52 patients, comprising three quarters Australian and one quarter
Dutch patients, who were also prospectively enrolled. In both the
test (161 patients) and validation cohorts (52 patients), there was
wide variability of alleles. The distribution of genotypes in both test
and validation cohorts was similar.
An NDMT/E ratio of 35 (95% CI 21.29e55.89) corresponded to an
endoxifen level of 15 nM in the test cohort. We thus categorized
patients with NDMT/E 35 and greater (corresponding to endoxifen
level of below 15 nM) as slow CYP2D6 metabolism (SM), whereas
patients with NDMT/E less than 35 were categorized as normal
CYP2D6 metabolism (NM). This threshold was validated by the
validation cohort.
We then examined NDMT/E in single alleles *1 and *2, which
are traditionally considered ‘wildtype’ using codeine as a substrate
to measure CYP2D6 activity. In the test cohort, there were 114 al-
leles that were *1. In these 114 alleles, the mean NDMT/E was 17.5
(range 0.12e150.33) and only 7 (6%) had a ratio >35. In the test
cohort, 74 alleles were *2 wildtype. The mean NDMT/E ratio for
these single *2 wildtype alleles was 23.5 (range 0.17e156.30) and
10 (13.5%) had a ratio >35.
In the validation cohort, 38 single alleles were *1 with a mean
NDMT/E of 17.2 (range 0.17e87.3) and 2 (5%) had a ratio >35.
Twenty-one were *2 with a mean NDMT/E of 21.79 (range
19.33e54.63) and one (5%) with a NDMT/E > 35.
Diplotype stratification according to NDMT/E is shown in Table 1
and Fig. 1 for the test cohort and Supplement Table 1 and
Supplement Figure 1 for the validation cohorts. These dataTable 1
Test Cohort stratified per diplotype.
Diplotype Frequency Mean NDMT/E Range Crews Ph
*1*1 28 12.2 7.5e23.9 EM
*1*2 29 13.5 0.12e38.6 EM
*1*9 1 13.5 13.5 EM
*1*41 4 15.1 11.54e18.3 EM
*2*15 1 18.6 18.6 EM
*2*9 4 24.1 15.82e32.3 EM
*2*41 4 24.5 19.02e29.7 EM
*2*10 2 26.3 20.61e31.909 EM
*1*4 20 26.7 0.16e96.64 EM
*2*2 11 28.2 0.17e81 EM
*2*3 3 28.8 21.9e39.7 EM
*4*9 1 31.1 31.1 IM
*10*10 7 39.0 24.83e60.28 EM
*9*41 1 39.9 39.9 IM
*2*4 10 43.8 8.4e156.3 EM
*10*41 1 44.9 44.9 EM
*41*41 5 46.2 32.26e56.52 EM
*9*9 1 49.1 49.1 IM
*1*10 4 56.1 14.42e150.32 EM
*3*4 3 68.6 23.20e118.9 PM
*4*41 3 87.7 53.03e144.2 IM
*3*41 2 88.7 26.98e150.43 IM
*4*4 14 100.5 10.41e291.42 PM
*1*15 1 102.0 102.0 EM
*3*3 1 115.5 115.5 PM
231demonstrate that diplotype describes NDMT/E as expected, with
wt/wt diplotypes and wt/V diplotypes tending to have lowNDMT/E
ratio (higher CYP2D6 activity) and V/V diplotypes tending to have
the highest NDMT/E ratio (lower CYP2D6 activity).
We then compared the NDMT/E ratio with genotype using the
complex standard classification system. As seen in Fig. 2, when 117
patients with normal metabolizer status (NDMT/E < 35) were
categorized using the current phenotype system, three were PM
(3%), two were IM (2%) and 112 were EM (96%). The standard sys-
tem was therefore good at identifying true normal metabolizers.
However, in 44 patients with slow CYP2D6 metabolism (NDMT/
E > 35), using the standard system 15 were PM (34%), six were IM
(14%) and 23 were EM (52%). Thus, a minority of patients who
would be predicted to have ineffective CYP2D6 activity using the
standard system had slow metabolism. Conversely, less than half
the EM patients had normal CYP2D6 metabolism (likely to have
effective endoxifen level).
Using our simplified system, where wt/wt is assumed to result
in normal metabolism, and wt/V and V/V remain uncertain, only 3
of 44 patients (7%) with low CYP2D6 activity as measured by
NDMT/E > 35, were misclassified as potentially normal metabo-
lizers (wt/wt; Fig. 3).


























Fig. 2. Test Cohort Stratification by Crews categorization i.e. EM, IM and PM by NDMT/
E ratio <35 and >35. *<35 is normal metabolizer; ratio >35 is slow metabolizer.
Fig. 3. Test cohort: Stratification of wt/wt, wt/V and V/V by NDMT/E ratio*. *<35 is
normal metabolizer; ratio >35 is slow metabolizer.
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simplified system had higher specificity (96%) but lower sensitivity
(44%) compared with the standard method which had a sensitivity
of 81% and specificity of 83%. (Table 2). Therefore, the simplifiedTable 2
Current phenotype vs. simplified phenotype classification for SM in test cohort.





Slow metabolizer (NDMT/EDF> 35)
N¼ 44





232method more accurately identified patients who were not slow
metabolizers. That is, the wt/wt patients in the simplified system
were less likely to actually have slow metabolism than those
categorized as EM by the standard phenotype system.
These results were validated in the validation cohort. In the test
cohort, when stratified by the standard classification system, slow
metabolizer status was found in 17% of EM, 75% of IM, and 83% of
PM patients (Table 2). Using the simplified classification system, the
likelihood of having slow CYP2D6metabolismwas 4% of wt/wt, 20%
of wt/V, and 77% of V/V patients.4. Discussion
The overarching aim of our study was to find the optimal
method of CYP2D6 phenotyping in tamoxifen treated patients to
predict slow CYP2D6 activity and hence imply low endoxifen level.
Our study tested the standard phenotypingmethod and a proposed
simplified method for categorizing CYP2D6 variants. CYP2D6 me-
tabolizes N-desmethyl-tamoxifen (NDMT) to endoxifen (E) and we
used the ratio of these twometabolites tomeasure CYP2D6 enzyme
activity. In a test cohort, we found that an NDMT/E ratio of above 35
correlated with a low endoxifen level and thus slow CYP2D6
metabolism. This ratio was subsequently validated in our validation
cohort.
An endoxifen threshold of 15 nM was used to derive the ratio, a
level shown in two retrospective studies to correlate with worse
breast cancer outcome in tamoxifen treated patients [6,7]. We
acknowledge that this threshold was not reproduced in two other
recent studies [23,24], although we suggest that these findings be
interpreted with caution [25,26]. The adjuvant CYPTAM study [27]
examined clinical outcome at three years, too brief an interval to
assess relapse and cancer-specific outcomes in a luminal breast
cancer population. The Neven et al. [26] paper, studied patients
who were treated in multiple settings e neoadjuvant, metastatic
firstline and metastatic secondline e thus introducing multiple
possible confounding factors.
In our study, we also acknowledge the small size of our study,
and that extensive patient characteristics were not analysed-thus
our results should be interpreted in this context and with these
considerations. We have previously shown that if endoxifen levels
are measured and are found to be lower than 15 nM, (24% of pa-
tients) incremental dose increase in tamoxifen will lead to higher
levels in 75% of patients who had endoxifen level <15 nM at
baseline on a daily 20 mg dose of tamoxifen [21].
We have previously argued that the best way to ensure effective
endoxifen level is to undertake therapeutic monitoring [21].
However, we acknowledge the popularity of CYP2D6 genotype
which may infer endoxifen level. For CYP2D6 genotype to be clin-
ically useful it should accurately predict slow metabolizer status
(and low endoxifen level) or ‘not-slow’ metabolizer status (and
effective endoxifen level). We contend that it is not clinically rele-
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44%
96%
C.I. Lee, S.K. Low, R. Maldonado et al. The Breast 54 (2020) 229e234these two categories for tamoxifen treatment. Using our simplified
system, we found that 93% of slow metabolizer patients had any
variant present (wt/V or V/V) and this was 100% in the validation
cohort. Conversely, slow metabolizer patients displayed wt/wt
genotype in only 7% and 0% of the test and validation cohorts,
respectively.
In our study, the standard CYP2D6 phenotype system, which
consists of four categories, was poor at identifying patients with
slowmetabolism. Only 48% of slowmetabolizer patients were IM or
PM using the standard phenotype system (57% in the validation
cohort). Conversely, slow metabolizer patients were inaccurately
classified as EM status in 52% of cases (43% of validation cohort).
This comparison clearly illustrates that, in our patient group, the
simplified phenotype method was superior to the standard method
in identifying patients who are not CYP2D6 slow metabolizers. If
validated by further groups, our findings will have clinical rele-
vance since it has the potential to simplify the interpretation of
CYP2D6 by clinicians.
Using the simplified phenotype system, patients with wild type
diplotype (*1 or *2), (represented by approximately 40% of our test
cohort patients), are highly likely to have normal metabolism with
an endoxifen level above 15 nM, if compliant with treatment and
have no issues with absorption. We propose these patients should
start tamoxifen with a 20 mg daily and have an endoxifen level
measured after at least 2 months of treatment.
Our study indicates that patients with any variant present are
more likely to have a low endoxifen level than those without a
genotype variant. Importantly, this means that determination of
diplotype (as opposed to single alleles) may not be required. Pa-
tients with any CYP2D6 genetic variant present (alleles other than
*1 or *2), represented by approximately 60% of the test cohort, have
a moderate to high chance of having slow metabolism, and the
diplotype alone is not accurate enough to predict this. In this
population, it would be wise to start with a higher dose to ensure
adequate endoxifen levels. As side effects are not dose-related
[21,27], we recommend starting with a 40 mg tamoxifen dose
and then perform therapeutic monitoring of endoxifen concentra-
tions. In those patients who still have a low endoxifen level, a
further dose escalation could be considered [21].
Variant diploid patients using the simplified system (V/V) or
those who are PM by the standard categorization, have a higher
chance of being slow metabolizers and very low endoxifen levels.
Such patients may not achieve adequate endoxifen levels evenwith
tamoxifen dose increase [6,7], and we advise the consideration of
alternative endocrine therapy, such as an aromatase inhibitor.
We acknowledge that tamoxifen is not used in all patients with
breast cancer and that alternatives exist [28] [-33]. In the adjuvant
setting, for premenopausal women whose disease characteristics
are adverse enough to require adjuvant chemotherapy, adjuvant
aromatase inhibitor in combination with ovarian function sup-
pression is the gold standard endocrine manouvre [34e36]. How-
ever, for premenopausal women with relatively low-risk disease,
adjuvant tamoxifen is still standard of care and remains an option
for postmenopausal women who do not tolerate aromatase in-
hibitors. In the metastatic setting where many therapies are
available, tamoxifen is still a valid later line therapy. Irrespective of
how tamoxifen treatment is used, we propose that tamoxifen dose
should be determined by direct measurement of endoxifen and by
checking CYP2D6 phenotype.
5. Conclusions
In conclusion, our results demonstrate that a simplified method
for classifying CYP2D6 phenotype using the presence or absence of
any genotype variant is superior to the standard phenotype233classification in determining slowmetabolizer status in tamoxifen-
treated patients. We have made recommendations based on this
simplified system regarding the starting dose of tamoxifen, when to
use therapeutic monitoring, and when to consider an alternative
endocrine therapy.
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